Olaparib
- Generic Name
- Olaparib
- Brand Names
- Lynparza
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23FN4O3
- CAS Number
- 763113-22-0
- Unique Ingredient Identifier
- WOH1JD9AR8
- Background
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death.
...
- Indication
Ovarian cancer
Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...
- Associated Conditions
- Advanced Epithelial Ovarian Cancer, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, High risk, early breast cancer, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Pancreas, Metastatic Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Pancreatic Adenocarcinoma Metastatic, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Stage I Breast Cancer, Advanced high-grade epithelial ovarian cancer, Advanced, high-grade Primary Peritoneal Cancer, High-grade advanced Fallopian Tubes Cancer, Recurrent platinum sensitive primary peritoneal cancer, Relapsed Platinum-Sensitive Epithelial Ovarian Cancer, Relapsed platinum sensitive primary peritoneal cancer, Relapsed platinum-sensitive fallopian tube cancer
- Associated Therapies
- Maintenance therapy
Pembrolizumab in Combination with Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Yuan Yuan
- Target Recruit Count
- 20
- Registration Number
- NCT03025035
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).
- Conditions
- Interventions
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT03022409
- Locations
- 🇨🇳
Research Site, Taipei, Taiwan
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
- Conditions
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 70
- Registration Number
- NCT03012321
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
🇺🇸Northwestern Medicine, Chicago, Illinois, United States
Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations
- First Posted Date
- 2017-01-04
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT03009682
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
- Conditions
- Recurrent Gastroesophageal Junction AdenocarcinomaStage III Esophageal Cancer AJCC v7Metastatic Gastric CarcinomaRecurrent Esophageal CarcinomaStage III Gastric Cancer AJCC v7Stage IV Esophageal Cancer AJCC v7Metastatic Esophageal CarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaUnresectable Esophageal CarcinomaUnresectable Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT03008278
- Locations
- 🇺🇸
City of Hope Antelope Valley, Lancaster, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸City of Hope Upland, Upland, California, United States
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
- Conditions
- Interventions
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 387
- Registration Number
- NCT02987543
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
- Conditions
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 272
- Registration Number
- NCT02983799
- Locations
- 🇨🇦
Research Site, Sherbrooke, Quebec, Canada
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT02974621
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT02953457
- Locations
- 🇺🇸
The Feinstein Institute for Medical Research/Lennox Hill Hospital, New York, New York, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.